Congestive Heart Failure: Worldwide Drug and Medical Device Markets

Chapter One: Executive Summary

Background
Scope and Methodology
Size and Growth of Market
Market Trends
The Nature of the Industry
The New Technologies
• Pharmaceutical
• Medical Device

Chapter Two: Overview of Congestive Heart Failure

Background
Pathophysiology
• Types of Heart Failure
• Theories of Congestive Heart Failure

Conditions Leading to Congestive Heart Failure
• Myocardial Infarction
• Hypertension
• Cardiomyopathy
• Atrial Fibrillation
• Other Risk Factors

Diagnosis of Congestive Heart Failure
Classification of Patients
Epidemiology
• United States
• Europe
• Japan

Chapter Three: Treatment of Congestive Heart Failure

Pharmacologic Therapy
• Overview
• Standard Pharmacologic Therapy
• The Market for CHF Pharmaceuticals
• Leading Products
• Leading Competitors

Congestive Heart Failure Devices
• Overview
• Bridge to Transplant
• Extended Use
• ACC Guidelines
• Intervention Device Products
• The Market for Intervention Devices
• Leading Products
• Leading Competitors

Guidelines for Management of Chronic Heart Failure
Strategies to Maintain Quality Patient Care and Contain Costs
• Patient Education Programs
• Dedicated Multidisciplinary Congestive Heart Failure Clinics

Chapter Five: Emerging Technologies To Treat Congestive Heart Failure

Pharmacologic Treatments
Medical Devices
Biotechnology

Chapter Six: Company Profiles

Abiomed, Inc.
Acorn Cardiovascular, Inc.
Actelion Ltd.
Arrow International
Bioheart, Inc.
CardioEnergetics, Inc.
CV Therapeutics
GenVec, Inc.
Geron Corporation
Guidant Corporation
MediGene AG
MedQuest Products, Inc.
Medtronic, Inc.
MicroMed Technology, Inc.
Myocor, Inc.
Myogen
St. Jude Medical
Somanetics Corporation
Texas Biotechnology Corporation
Thoratec Corporation

Chapter Seven: Conclusions and Strategic Implications

Prevention Over Treatment
Medical Approaches Over Surgical Approaches
Accelerating Device Development
Device Competition Heats Up
Big Pharma Still Dominant
Biotech Emerges
Transplant Alternatives on the Way
Drug Market Outpaces Epidemiology

Chapter One: Executive Summary

Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World Healthcare Markets, 2000-2008
Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World Healthcare Markets, 2000-2008
Figure 1-3: The Total Market for Congestive Heart Failure Therapeutics in the Major World Healthcare Markets: 2000-2008
Table 1-1: Estimated Market Sizes for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008
Table 1-2: Estimated Market Sizes for CHF Devices in the Major World Healthcare Markets, 2000-2008
Figure 1-4: Trending in the World’s Major Congestive Heart Failure Therapy Markets (Total), 2000-2008
Figure 1-5: Composition of the Markets for Congestive Heart Failure Therapeutics by Product Classification: 2000-2008
Table 1-3: Key Competitors in Congestive Heart Failure Therapeutics

Chapter Two: Overview of Congestive Heart Failure

Table 2-1: Common Contributors to Congestive Heart Failure
Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World’s Major Healthcare Markets, 2000-2008
Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World Healthcare Markets, 2000-2008
Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World Healthcare Markets, 2000-2008
Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 1999
Table 2-2: Incidence and Prevalence of CHF in the United States: 2000-2008
Figure 2-5: Incidence and Prevalence of CHF in the United States: 2000-2008
Figure 2-6: Prevalence of Congestive Heart Failure in the United States by Age and Sex: 1988-1994
Figure 2-7: The Distribution of Congestive Heart Failure Among the Five Major European Healthcare Markets, 2002
Table 2-3: Incidence and Prevalence of CHF in the Major European Healthcare Markets, 2000-2008
Figure 2-8: Incidence and Prevalence of CHF in the Major European Healthcare Markets, 2000-2008
Table 2-4: Incidence and Prevalence of CHF in the Japanese Healthcare Market, 2000-2008
Figure 2-9: Incidence and Prevalence of CHF in the Japanese Healthcare Market, 2000-2008

Chapter Three: Management of Congestive Heart Failure

Table 3-1: Therapeutic Strategies for Symptomatic Congestive Heart Failure
Table 3-2: Pharmacologic Response to the Pathophysiology of Cardiac Performance
Table 3-3: Common ACE Inhibitors Available for the Treatment of CHF
Table 3-4: Common Angiotensin II Receptor Antagonists Available for the Treatment of CHF
Table 3-5: Common â-Receptor Antagonists Available for the Treatment of CHF
Table 3-6: Common Diuretics Available for the Treatment of CHF
Table 3-7: Common Inotropic Drugs Available for the Treatment of CHF
Table 3-8: Common Vasodilators Available for the Treatment of CHF
Table 3-9: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008
Figure 3-1: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008
Figure 3-2: Distribution of the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, 2000-2008
Table 3-10: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the United States, 2000-2008
Figure 3-3: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the United States, 2000-2008
Figure 3-4: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the United States, 2000-2008
Table 3-11: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major European Markets: 2000-2008
Figure 3-5: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major European Markets, 2000-2008
Figure 3-6: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the Major European Markets, 2000-2008
Table 3-12: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in Japan, 2000-2008
Figure 3-7: Trending in the Estimated Historic and Forecast Markets For CHF Pharmaceuticals in the Major Japanese Markets, 2000-2008
Figure 3-8: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the Major Japanese Markets, 2000-2008
Table 3-13: Companies Actively Addressing the CHF Pharmaceutical Markets
Table 3-14: Key Competitors in the CHF Pharmaceutical Arena
Table 3-15: Guidelines for the Choice of Pacemaker Generator In Selected Indications for Pacing
Table 3-16: Biventricular Pacemakers for CHF Therapy
Table 3-17: Cardioverter/Defibrillators (ICD) Available for Use in the Treatment of CHF
Table 3-18: Ventricular Assist Devices (VADs) On the Market and in Development
Table 3-19: The Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment
Figure 3-9: Trending in the Estimated Markets for Devices to Treat CHF In the Major World Healthcare Markets by Geographic Segment
Figure 3-10: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment
Table 3-20: Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment
Figure 3-11: Trending in the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment
Figure 3-12: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment
Table 3-21: The Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment
Figure 3-13: Trending in the Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment
Figure 3-14: Distribution of the Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment
Table 3-22: The Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets by Device Segment
Figure 3-15: Trending in the Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets by Device Segment
Figure 3-16: Distribution of the Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets By Device Segment
Table 3-23: The Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment
Figure 3-17: Trending in the Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment
Figure 3-18: Distribution of the Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment

Chapter Four: Congestive Heart Failure Patient Management

Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of Congestive Heart Failure by Stage of the Disease
Table 4-1: ACC/AHA Staging of Congestive Heart Failure
Table 4-2, 2001 ACC/AHA Guidelines for Evaluation and Treatment for Congestive Heart Failure

Chapter Five: Emerging Technologies To Treat CHF

Table 5-1: New Drugs in Development for the Treatment of Congestive Heart Failure
Table 5-2: Medical Devices in Clinical Trials for the Treatment of Congestive Heart Failure
Table 5-3: Biotechnology-Based Therapeutics for Congestive Heart Failure in Development